Antibody-Drug Conjugates in Solid Tumors: Mechanisms, Clinical Advances, and Emerging Resistance Patterns
ASIDE Oncology · 2026
DOI: 10.71079/aside.onc.012026464 ↗Kurz gefasst
Fachartikel in der Zeitschrift ASIDE Oncology, 2026. Verfasst von Hassan A. Abdou und 1 weiteren Autor:innen. Die Arbeit nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Antibody-drug conjugates (ADCs) represent a transformative therapeutic modality in oncology, combining targeted antibody delivery with potent cytotoxic payloads. This narrative literature review examines ADC development for solid tumors, emphasizing advances from 2022-2025 while incorporating foundational trials from 2017-2021.
Methods
We conducted comprehensive searches of PubMed, Embase, and major oncology conference proceedings (ASCO, ESMO, AACR) from January 2020 through December 2025, with emphasis on literature published since 2022. Search terms included: antibody-drug conjugates, ADC, solid tumors, specific agent names (trastuzumab deruxtecan, sacituzumab govitecan, enfortumab vedotin, tisotumab vedotin, datopotamab deruxtecan), resistance mechanisms, and combination therapy. We prioritized phase 2 and 3 clinical trials, mechanistic studies, and high-quality systematic reviews, clearly distinguishing phase 2 response data from comparative survival outcomes.
Results
Topoisomerase inhibitor-based ADCs demonstrated substantial activity across multiple tumor types. In HER2-positive breast cancer, trastuzumab deruxtecan achieved superior outcomes compared to trastuzumab emtansine in DESTINY-Breast03. HER2-targeted ADCs achieve higher response rates than tissue antigen-targeted ADCs, though comparisons are limited by population heterogeneity. Multiple resistance mechanisms include antigen downregulation, impaired internalization, and payload efflux. Established targets (HER2, TROP2, Nectin-4) have FDA-approved ADCs, while emerging targets (B7H3, CEACAM5) are under investigation. Combination strategies with immunotherapy show promising synergy.
Conclusions
ADCs have established clinical utility across solid tumors, with ongoing innovation in linker technology, payload selection, and target identification. Next-generation ADCs incorporating bispecific antibodies and dual payloads represent promising directions. Definitive evidence of improved long-term outcomes is needed before widespread adoption in curative-intent settings.
Zitieren
APA
Abdou, H. A., & Awny, S. (2026). Antibody-Drug Conjugates in Solid Tumors: Mechanisms, Clinical Advances, and Emerging Resistance Patterns. ASIDE Oncology. https://doi.org/10.71079/aside.onc.012026464
Vancouver
Abdou HA, Awny S. Antibody-Drug Conjugates in Solid Tumors: Mechanisms, Clinical Advances, and Emerging Resistance Patterns. ASIDE Oncology. 2026. doi:10.71079/aside.onc.012026464
BibTeX
@article{Abdou2026,
author = {Abdou, Hassan A. and Awny, Shadi},
title = {Antibody-Drug Conjugates in Solid Tumors: Mechanisms, Clinical Advances, and Emerging Resistance Patterns},
journal = {ASIDE Oncology},
year = {2026},
doi = {10.71079/aside.onc.012026464}
}
EUVIMED